Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2024-12-13 Capital/Financing Update
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
BioSenic - PR TrialCap (EN) - final.pdf
Capital/Financing Update Classification · 99% confidence The document is explicitly labeled as a 'RELEASE' and 'PRESS RELEASE – INSIDE INFORMATION'. The content details a conditional letter of intent signed by a subsidiary (Medsenic) regarding a potential financing arrangement (loan and equity investment) to cover clinical trial costs. This announcement concerns fundraising, capital structure changes (creation of an Australian subsidiary to receive funds), and debt/equity discussions. This aligns directly with the definition of 'Capital/Financing Update' (CAP). It is not a full Annual Report (10-K), an Earnings Release (ER), or a simple Dividend Notice (DIV). Since it is a detailed announcement of a specific financial transaction, it is classified as CAP rather than the general fallback (RNS). The document length is substantial (8743 chars), indicating it is the primary announcement, not just a notification of publication (RPA).
2024-12-13 English
BioSenic - PR TrialCap - final.pdf
Capital/Financing Update Classification · 99% confidence The document is explicitly titled "COMMUNIQUÉ DE PRESSE – INFORMATION PRIVILÉGIÉE" (Press Release – Privileged Information) and is dated 13/12/2024. It announces a significant corporate event: the signing of a conditional letter of intent (LOI) for a financing deal (loan and equity subscription) related to clinical trial costs for a subsidiary (Medsenic). This type of announcement, detailing strategic corporate actions, financing, or material agreements, is typically classified as an Earnings Release (ER) if it contains key financial highlights, or a Regulatory Filing (RNS) if it's a general market disclosure. Since it details specific financial arrangements (loan amounts, equity participation, interest rates) and strategic developments, it functions as an immediate disclosure of material information. Given the context of a press release announcing a major financing/strategic step, it aligns best with the 'Earnings Release' (ER) category, which often encompasses immediate material financial news, or 'Regulatory Filings' (RNS) as a broad disclosure. However, because it is a formal press release detailing financial arrangements and strategic progress (even if conditional), and not just a short notice of publication, 'ER' is a strong candidate, but 'RNS' is the safest fallback for non-standard, material press releases. Given the content is primarily about a potential financing deal and clinical trial progress, and it is structured as a formal press release, it is most accurately classified as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it were tied to a reporting period. Since it's a specific, material, non-periodic announcement, RNS is the most appropriate catch-all for significant, non-standard disclosures not covered by other specific codes like CAP or TAR. I will lean towards RNS as it is a general regulatory announcement via press release.
2024-12-13 French
BIOS_PR_2024_October_Denominator_EN_final.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly labeled as a "PRESS RELEASE – REGULATED INFORMATION" dated 31/10/2024. The core content details an "increase in the total number of voting rights and shares" due to new share issuance, providing specific figures for the total number of shares and voting rights as of October 31, 2024. This directly relates to changes in the company's capital structure and share count, which is a mandatory disclosure. This type of announcement, detailing changes in the total number of shares/voting rights (the denominator for various calculations), aligns best with the 'Share Issue/Capital Change' category (SHA). While it involves share numbers, it is not a report of management buying back shares (POS), but rather a formal notification of a capital structure change resulting from issuance. It is not a general regulatory filing (RNS) because a more specific category exists.
2024-10-31 English
BIOS_PR_2024_octobre_Denominator_FR_final.pdf
Share Issue/Capital Change Classification · 99% confidence The document is titled "COMMUNIQUE DE PRESSE – INFORMATION REGLEMENTEE" (Press Release - Regulated Information) and is dated 31/10/2024. The core content details an announcement regarding the 'Information relative au nombre total de droits de vote et d'actions' (Information relative to the total number of voting rights and shares). Specifically, it reports the issuance of new shares and updates the total number of shares and voting rights as of October 31, 2024, referencing Belgian law regarding significant shareholdings. This type of announcement, which reports changes in the total number of shares or voting rights, directly corresponds to a notification about changes in capital structure or share ownership thresholds. While it involves share numbers, it is not a formal capital increase filing (CAP) or a general major shareholding notification (MRQ) which usually reports an investor crossing a threshold. Instead, it is a mandatory disclosure of the resulting share count. This fits best under 'Share Issue/Capital Change' (SHA) as it explicitly details the result of new share issuance, or potentially 'Major Shareholding Notification' (MRQ) if interpreted broadly as a change in the denominator, but SHA is more precise for reporting the *result* of an issuance. Given the explicit mention of 'nombre total d'actions nouvelles émises' (number of new shares issued), SHA is the most appropriate classification.
2024-10-31 French
BIOS_PR_Q3-2024_EN.pdf
Earnings Release Classification · 99% confidence The document is explicitly titled "PRESS RELEASE – REGULATED INFORMATION" and provides a "Business Update for the third quarter, ended 30 September 2024." It details key operational, patent, management, and financial highlights for the period. This structure—a formal announcement of periodic business and financial performance highlights—aligns perfectly with the definition of an Earnings Release (ER). Although it contains some M&A mentions, the primary purpose is the quarterly update. It is not a full 10-K, a comprehensive IR, or just a simple announcement of a report (RPA/RNS), but the actual content of the periodic results announcement. Q3 2024
2024-10-28 English
BIOS_PR_Q3-2024_FR.pdf
Earnings Release Classification · 99% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE – INFORMATION REGLEMENTÉE" (Press Release – Regulated Information) and is dated 28/10/2024. It provides an update on the company's activities for the third quarter, closing on September 30, 2024, including operational milestones, management changes, and key financial figures (unaudited net cash). This structure—a formal, periodic update summarizing recent performance and outlook, issued via a press release—is characteristic of an Earnings Release (ER) or an Interim/Quarterly Report (IR). Since it focuses on key highlights, financial elements (though brief), and operational updates for a specific quarter (Q3), it aligns best with the definition of an Earnings Release (ER), which is the initial announcement of periodical financial results (key highlights only). It is not a full 10-K, nor is it a transcript (CT) or a formal presentation (IP). It is too detailed for a simple Report Publication Announcement (RPA). 9M 2024
2024-10-28 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.